These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17728024)

  • 21. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
    Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.
    Hessel A; Savidis-Dacho H; Coulibaly S; Portsmouth D; Kreil TR; Crowe BA; Schwendinger MG; Pilz A; Barrett PN; Falkner FG; Schäfer B
    PLoS One; 2014; 9(2):e88340. PubMed ID: 24523886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge.
    Kingstad-Bakke B; Kamlangdee A; Osorio JE
    Vaccine; 2015 Sep; 33(39):5155-62. PubMed ID: 26271828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge.
    Prabakaran M; Kolpe AB; He F; Kwang J
    Vaccine; 2013 Feb; 31(10):1385-92. PubMed ID: 23328313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenoviral vector expressing murine β-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice.
    Vemula SV; Pandey A; Singh N; Katz JM; Donis R; Sambhara S; Mittal SK
    Virus Res; 2013 Oct; 177(1):55-61. PubMed ID: 23892144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus.
    Vitelli A; Quirion MR; Lo CY; Misplon JA; Grabowska AK; Pierantoni A; Ammendola V; Price GE; Soboleski MR; Cortese R; Colloca S; Nicosia A; Epstein SL
    PLoS One; 2013; 8(3):e55435. PubMed ID: 23536756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.
    Price GE; Soboleski MR; Lo CY; Misplon JA; Pappas C; Houser KV; Tumpey TM; Epstein SL
    Vaccine; 2009 Nov; 27(47):6512-21. PubMed ID: 19729082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.
    Park KS; Lee J; Ahn SS; Byun YH; Seong BL; Baek YH; Song MS; Choi YK; Na YJ; Hwang I; Sung YC; Lee CG
    Virology; 2009 Dec; 395(2):182-9. PubMed ID: 19836045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge.
    Kheiri MT; Jamali A; Shenagari M; Hashemi H; Sabahi F; Atyabi F; Saghiri R
    Antiviral Res; 2012 Sep; 95(3):229-36. PubMed ID: 22809863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.
    Wang W; Li R; Deng Y; Lu N; Chen H; Meng X; Wang W; Wang X; Yan K; Qi X; Zhang X; Xin W; Lu Z; Li X; Bian T; Gao Y; Tan W; Ruan L
    Clin Vaccine Immunol; 2015 Jun; 22(6):618-30. PubMed ID: 25834017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses.
    Holman DH; Wang D; Raja NU; Luo M; Moore KM; Woraratanadharm J; Mytle N; Dong JY
    Vaccine; 2008 May; 26(21):2627-39. PubMed ID: 18395306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice.
    Bodewes R; Kreijtz JH; Hillaire ML; Geelhoed-Mieras MM; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    J Gen Virol; 2010 Jul; 91(Pt 7):1743-53. PubMed ID: 20335492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus.
    Hung JT; Tsai YC; Lin WD; Jan JT; Lin KH; Huang JR; Cheng JY; Chen MW; Wong CH; Yu AL
    Antiviral Res; 2014 Jul; 107():110-8. PubMed ID: 24786174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine.
    Wu Q; Xiao S; Fan H; Li Y; Xu J; Li Z; Lu W; Su X; Zou W; Jin M; Chen H; Fang L
    Antiviral Res; 2011 Dec; 92(3):493-6. PubMed ID: 22020305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies.
    Roos A; Roozendaal R; Theeuwsen J; Riahi S; Vaneman J; Tolboom J; Dekking L; Koudstaal W; Goudsmit J; Radošević K
    Vaccine; 2015 Mar; 33(14):1739-47. PubMed ID: 25659276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge.
    Epstein SL; Stack A; Misplon JA; Lo CY; Mostowski H; Bennink J; Subbarao K
    Int Immunol; 2000 Jan; 12(1):91-101. PubMed ID: 10607754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress on adenovirus-vectored universal influenza vaccines.
    Xiang K; Ying G; Yan Z; Shanshan Y; Lei Z; Hongjun L; Maosheng S
    Hum Vaccin Immunother; 2015; 11(5):1209-22. PubMed ID: 25876176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.
    Lalor PA; Webby RJ; Morrow J; Rusalov D; Kaslow DC; Rolland A; Smith LR
    J Infect Dis; 2008 Jun; 197(12):1643-52. PubMed ID: 18513153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice.
    He F; Prabakaran M; Rajesh Kumar S; Tan Y; Kwang J
    Antiviral Res; 2014 May; 105():143-51. PubMed ID: 24637255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.